DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w3b27r/pharmapoint) has announced the addition of the "China Atopic Dermatitis Report - Sales Forecast and Market Analysis to 2022" report to their offering.
Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
By the mid-to-late term of Our 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.
This is attributed to the low drug treatment rates in that market, which lower the aforementioned patient pool to 3.3 million, and also because that market is saturated with generic topical therapies. Nonetheless, similar market dynamics to that of the 7MM are at play in the Chinese market, in that topical corticosteroids and moisturizers/emollients dominate the treatment landscape, with 60%-90% of patients across all severities receiving these therapies.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
- Protopic (tacrolimus)
- Other Therapeutic Drug Classes Used in Atopic Dermatitis
6 Opportunity and Unmet Need
- A Systemic Drug for Severe Recalcitrant Patients
- Tests that Stratify Patients and Allow for a Tailored Treatment Approach
- A Drug that Effectively Controls Patients' Pruritus
- Further Research into the Pathophysiology of Atopic Dermatitis
- A Drug that Induces Disease Remission
- Improved Quality of Life for Both Patients and their Carers
- Increase Treatment Armamentarium for Severe Recalcitrant Patients
- Predictive Tests for Patient Stratification
- More Therapeutic Options that Address Patients' Pruritus
7 Pipeline Assessment
8 Market Outlook
Anticipated launch of the first biologic for the treatment of moderate to severe disease
The underserved severe refractory patient segment presents an untapped market opportunity
A drug that is able to target two or more atopic diseases would gain a foothold in these markets
Atopic dermatitis presents an attractive patient population for drug developers
Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents
- First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market
- The largest atopic dermatitis patient segment - mild disease - can be well-controlled on most forms of topical therapy
- Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products
- The complexity of the multiple etiologies that lead to atopic dermatitis means that treatment outcomes with existing drugs are not universal across all patient groups
- A significant proportion of patients experience disease remission in their early adolescent years and this may occur without drug therapy
For more information visit http://www.researchandmarkets.com/research/w3b27r/pharmapoint